A detailed history of Level Four Advisory Services, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Level Four Advisory Services, LLC holds 8,893 shares of LLY stock, worth $7.08 Million. This represents 0.34% of its overall portfolio holdings.

Number of Shares
8,893
Previous 8,706 2.15%
Holding current value
$7.08 Million
Previous $7.88 Million 0.05%
% of portfolio
0.34%
Previous 0.37%

Shares

32 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$772.14 - $960.02 $144,390 - $179,523
187 Added 2.15%
8,893 $7.88 Million
Q2 2024

Aug 09, 2024

BUY
$724.87 - $909.04 $1.42 Million - $1.79 Million
1,964 Added 29.13%
8,706 $7.88 Million
Q4 2023

Feb 08, 2024

SELL
$525.19 - $619.13 $32,036 - $37,766
-61 Reduced 0.9%
6,742 $3.93 Million
Q3 2023

Nov 13, 2023

SELL
$434.7 - $599.3 $477,300 - $658,031
-1,098 Reduced 13.9%
6,803 $3.65 Million
Q2 2023

Jul 10, 2023

BUY
$350.74 - $468.98 $247,973 - $331,568
707 Added 9.83%
7,901 $3.71 Million
Q1 2023

Jun 05, 2023

SELL
$310.63 - $364.82 $552,610 - $649,014
-1,779 Reduced 19.83%
7,194 $2.47 Million
Q4 2022

Feb 13, 2023

BUY
$321.55 - $374.67 $1.05 Million - $1.22 Million
3,262 Added 57.12%
8,973 $3.28 Million
Q3 2022

Nov 07, 2022

BUY
$296.48 - $337.87 $111,476 - $127,039
376 Added 7.05%
5,711 $1.85 Million
Q2 2022

Aug 08, 2022

BUY
$278.73 - $327.27 $300,192 - $352,469
1,077 Added 25.29%
5,335 $1.73 Million
Q1 2022

May 10, 2022

BUY
$234.69 - $291.66 $93,171 - $115,789
397 Added 10.28%
4,258 $1.22 Million
Q4 2021

Feb 11, 2022

BUY
$224.85 - $279.04 $135,134 - $167,703
601 Added 18.44%
3,861 $1.07 Million
Q3 2021

Oct 12, 2021

SELL
$221.6 - $272.71 $590,120 - $726,226
-2,663 Reduced 44.96%
3,260 $753,000
Q2 2021

Aug 09, 2021

SELL
$180.55 - $233.54 $606,286 - $784,227
-3,358 Reduced 36.18%
5,923 $1.36 Million
Q1 2021

May 10, 2021

BUY
$164.32 - $212.72 $544,063 - $704,315
3,311 Added 55.46%
9,281 $1.73 Million
Q4 2020

Feb 10, 2021

BUY
$130.46 - $172.63 $25,439 - $33,662
195 Added 3.38%
5,970 $1.01 Million
Q3 2020

Nov 02, 2020

SELL
$146.22 - $169.13 $44,304 - $51,246
-303 Reduced 4.99%
5,775 $855,000
Q2 2020

Aug 17, 2020

BUY
$136.42 - $164.18 $829,160 - $997,886
6,078 New
6,078 $997,000
Q2 2020

Jul 27, 2020

SELL
$136.42 - $164.18 $612,116 - $736,675
-4,487 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$119.05 - $147.35 $44,405 - $54,961
-373 Reduced 7.67%
4,487 $623,000
Q4 2019

Feb 13, 2020

BUY
$106.92 - $132.43 $19,994 - $24,764
187 Added 4.0%
4,860 $643,000
Q3 2019

Nov 12, 2019

SELL
$106.79 - $116.16 $4,378 - $4,762
-41 Reduced 0.87%
4,673 $523,000
Q2 2019

Aug 14, 2019

SELL
$110.79 - $129.32 $45,867 - $53,538
-414 Reduced 8.07%
4,714 $522,000
Q1 2019

May 15, 2019

SELL
$111.31 - $131.02 $249,557 - $293,746
-2,242 Reduced 30.42%
5,128 $665,000
Q4 2018

Feb 08, 2019

BUY
$105.9 - $118.64 $44,795 - $50,184
423 Added 6.09%
7,370 $853,000
Q3 2018

Nov 14, 2018

BUY
$85.86 - $107.31 $17,343 - $21,676
202 Added 2.99%
6,947 $746,000
Q2 2018

Aug 14, 2018

BUY
$75.7 - $86.88 $142,770 - $163,855
1,886 Added 38.81%
6,745 $576,000
Q1 2018

May 14, 2018

SELL
$74.21 - $87.6 $24,860 - $29,345
-335 Reduced 6.45%
4,859 $376,000
Q4 2017

Feb 13, 2018

SELL
$81.94 - $87.89 $35,152 - $37,704
-429 Reduced 7.63%
5,194 $439,000
Q3 2017

Apr 03, 2018

SELL
$77.07 - $85.54 $78,996 - $87,678
-1,025 Reduced 15.42%
5,623 $481,000
Q3 2017

Nov 15, 2017

SELL
$77.07 - $85.54 $193,445 - $214,705
-2,510 Reduced 27.41%
6,648 $579,000
Q2 2017

Sep 20, 2017

SELL
N/A
-191 Reduced 2.04%
9,158 $784,000
Q1 2017

Sep 20, 2017

BUY
N/A
9,349
9,349 $800,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $756B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Level Four Advisory Services, LLC Portfolio

Follow Level Four Advisory Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Level Four Advisory Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Level Four Advisory Services, LLC with notifications on news.